Difference between revisions of "Serous carcinoma of the ovary"

From Libre Pathology
Jump to navigation Jump to search
Line 27: Line 27:
*Other non-ovarian serous carcinomas - ''see [[serous carcinoma]]''.
*Other non-ovarian serous carcinomas - ''see [[serous carcinoma]]''.
*[[Ovarian serous borderline tumour]] - mild to moderate nuclear atypia, no invasion, few mitoses.
*[[Ovarian serous borderline tumour]] - mild to moderate nuclear atypia, no invasion, few mitoses.
===Grading===
Serous carcinoma is subdivided into:<ref name=pmid22833081>{{Cite journal  | last1 = Garg | first1 = K. | last2 = Park | first2 = KJ. | last3 = Soslow | first3 = RA. | title = Low-grade serous neoplasms of the ovary with transformation to high-grade carcinomas: a report of 3 cases. | journal = Int J Gynecol Pathol | volume = 31 | issue = 5 | pages = 423-8 | month = Sep | year = 2012 | doi = 10.1097/PGP.0b013e31824ae6f2 | PMID = 22833081 }}</ref>
*Low-grade.
*High-grade.
Note:
*Tumours very rarely transform from ''low-grade'' to ''high-grade''.<ref name=pmid22833081/>


===Images===
===Images===

Revision as of 22:15, 1 January 2014

Serous carcinoma of the ovary, also ovarian serous carcinoma, is relatively common malignant ovarian tumour.

General

Microscopic

Features:

  • Marked nuclear pleomorphism:
    • Variation in size - usually marked.
    • Variation in staining.
    • Variation in shape.
  • Prominent nucleolus - key feature.
  • Eccentric nucleus.
  • Architecture:
    • Solid.
    • Papillary - classic.
    • Glandular - uncommon.
  • +/-Psammoma bodies - uncommon.
  • +/-Necrosis - often extensive.

DDx:

Grading

Serous carcinoma is subdivided into:[2]

  • Low-grade.
  • High-grade.

Note:

  • Tumours very rarely transform from low-grade to high-grade.[2]

Images

IHC

  • WT-1 +ve - key immunostain.[3]
  • CK7 +ve.
  • CA-125 +ve.
  • ER +ve.[4]
  • p53 +ve.

Others:

See also

References

  1. Vang, R.; Shih, IeM.; Kurman, RJ. (Jan 2013). "Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.". Histopathology 62 (1): 44-58. doi:10.1111/his.12046. PMID 23240669.
  2. 2.0 2.1 Garg, K.; Park, KJ.; Soslow, RA. (Sep 2012). "Low-grade serous neoplasms of the ovary with transformation to high-grade carcinomas: a report of 3 cases.". Int J Gynecol Pathol 31 (5): 423-8. doi:10.1097/PGP.0b013e31824ae6f2. PMID 22833081.
  3. Köbel, M.; Kalloger, SE.; Carrick, J.; Huntsman, D.; Asad, H.; Oliva, E.; Ewanowich, CA.; Soslow, RA. et al. (Jan 2009). "A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary.". Am J Surg Pathol 33 (1): 14-21. doi:10.1097/PAS.0b013e3181788546. PMID 18830127.
  4. DeLair, D.; Oliva, E.; Köbel, M.; Macias, A.; Gilks, CB.; Soslow, RA. (Jan 2011). "Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases.". Am J Surg Pathol 35 (1): 36-44. doi:10.1097/PAS.0b013e3181ff400e. PMID 21164285.
  5. Tsuchiya, A.; Sakamoto, M.; Yasuda, J.; Chuma, M.; Ohta, T.; Ohki, M.; Yasugi, T.; Taketani, Y. et al. (Dec 2003). "Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.". Am J Pathol 163 (6): 2503-12. PMID 14633622. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1892387/?tool=pubmed.
  6. Online 'Mendelian Inheritance in Man' (OMIM) 189907